Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sweta Jaiswal, FRM headshot

Pfizer's Coronavirus Vaccine Gets a Nod in UK: ETFs to Shine

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Sweta Killa headshot

After a Historic November, What Awaits ETFs in December?

Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.

Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.

Encouraging News on COVID-19 Vaccine

Encouraging News on COVID-19 Vaccine

Mark Vickery headshot

ADP Reports 307K New Jobs, Revisions Up

307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.

Sweta Killa headshot

5 International ETFs That Outstripped US Market in November

November was a banner month for the global stock market despite the rising number of COVID-19 cases.

Cimarex Energy (XEC) Up 48.6% QTD: What's Behind the Rally?

Improving oil prices on positive coronavirus vaccine results aid Cimarex (XEC).

Stock Market News for Dec 2, 2020

U.S. stock markets closed higher on Tuesday on the back of optimism surrounding COVID-19 vaccine.

Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Kinjel Shah headshot

Will Americans Get COVID-19 Vaccine Sooner Than Europeans?

Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe

Neena Mishra headshot

Small Cap ETFs Deliver Big Gains for Investors

November was the best month ever for the Russell 2000 index

Sweta Killa headshot

5 Stocks in Dow ETF That Powered the Best Month Since 1987

Amid rising COVID-19 cases, the Dow Jones wrapped up its best month in more than 30 years after hitting the major milestone of 30,000 for the first time last week.

Novavax (NVAX) Rises Despite U.S. Coronavirus Vaccine Study Delay

Novavax (NVAX) to begin a phase III study on NVX-CoV2373, its COVID-19 vaccine candidate in the United States and Mexico in the coming weeks. Shares up.

Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment

Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.

Moderna (MRNA) Seeks Nod for Emergency Use of COVID-19 Vaccine

Moderna's (MRNA) coronavirus vaccine achieves efficacy rate of 94.1% in primary efficacy analysis. The company files for Emergency Use Authorization to the FDA.

Ritujay Ghosh headshot

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

Tirthankar Chakraborty headshot

Stellar November Paves the Way for a Solid December: 5 Picks

Growth-oriented stocks like General Motors (GM), Malibu Boats (MBUU) and LaZBoy (LZB) are likely to do well this month on vaccine optimism and Yellen's possible appointment as US Treasury Secretary.

The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI

The Zacks Analyst Blog Highlights: NVIDIA, Pfizer, Abbott, UPS and ICICI

Moderna (MRNA) Amends Coronavirus Vaccine Supply Deal in U.K.

Moderna (MRNA) amends its present contract with the United Kingdom government to supply two million additional doses of its coronavirus vaccine candidate, mRNA-1273, upon approval.

Stock Market News for Nov 30, 2020

U.S. stock markets closed higher on Friday amid optimism surrounding COVID-19 vaccine.

Tirthankar Chakraborty headshot

5 of the Best Stocks to Buy Heading Into December

Progress toward a COVID-19 vaccine and Yellen likely to be selected for a top post certainly bode well for stocks in December. Some of the stocks worth investing in are Buckle (BKE) and Deere (DE).

Sanghamitra Saha headshot

Biotech ETF (XBI) Hits New 52-Week High

The biotech ETF hits a 52-week high on Nov 27. Can it soar further?

Markets Gear for a Different Black Friday

Markets Gear for a Different Black Friday

Sweta Killa headshot

Energy on Track for Its Best Month Ever: 5 ETF, Stock Winners

The S&P 500 Energy Index is on track for the best month ever, gaining nearly 40%.